Next Article in Journal
Sentiment Analysis Methods for HPV Vaccines Related Tweets Based on Transfer Learning
Previous Article in Journal
Relationship between Clinical Parameters and Chromosomal Microarray Data in Infants with Developmental Delay
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Health Information Technology and Doctor Shopping: A Systematic Review

School of Health Administration, Texas State University, San Marcos, TX 78666, USA
*
Author to whom correspondence should be addressed.
Healthcare 2020, 8(3), 306; https://doi.org/10.3390/healthcare8030306
Submission received: 24 July 2020 / Revised: 17 August 2020 / Accepted: 26 August 2020 / Published: 28 August 2020

Abstract

:
Doctor shopping is the practice of visiting multiple physicians to obtain multiple prescriptions. Health information technology (HIT) allows healthcare providers and patients to leverage records or shared information to improve effective care. Our research objective was to determine how HIT is being leveraged to control for doctor shopping. We analyzed articles that covered a 10-year time period from four databases and reported using preferred reporting items for systematic reviews and meta-analysis (PRISMA). We compared intervention, study design, and bias, in addition to showing intervention interactions with facilitators, barriers, and medical outcomes. From 42 articles published from six countries, we identified seven interventions, five facilitator themes with two individual observations, three barrier themes with six individual observations, and two medical outcome themes with four individual observations. Multiple HIT mechanisms exist to control for doctor shopping. Some are associated with a decrease in overdose mortality, but access is not universal or compulsory, and data sharing is sporadic. Because shoppers travel hundreds of miles in pursuit of prescription drugs, data sharing should be an imperative. Research supports leveraging HIT to control doctor shopping, yet without robust data sharing agreements, the efforts of the system are limited to the efforts of the entity with the least number of barriers to their goal. Shoppers will seek out and exploit that organization that does not require participation or checking of prescription drug monitoring programs (PDMP), and the research shows that they will drive great distances to exploit this weakest link.

1. Introduction

1.1. Rationale

The World Health Organization (WHO) encourages providers to remove impediments that prevent a patient’s voice from being heard [1,2,3]. However, the recent opioid epidemic serves as a reminder of systemic inefficiencies that push patients’ voice into unhealthy practices. Unchecked, these inefficiencies are deadly [4]. An example of this can be described by the practice of doctor shopping, which is the practice of individuals visiting several physicians to obtain multiple prescriptions or to attain a preferred medical diagnosis without distinct material gain [4]. It is also defined by imposing a threshold of 6 or more prescriptions from at least 6 different prescribers within 6 months’ time [4]. Such a specific description made our team wonder why health information technology (HIT) could not be leveraged to control for this practice. The simple answer may lie in the concept of interoperability or lack thereof because even countries with a national health system struggle with issues of interoperability [5]. In its simplest form, interoperability “enables the secure exchange of health information with, and use of electronic health information from, other health information technology without special effort on the part of the user” [6]. If physicians could quickly check to see if the patient had recently received the same prescription from another physician outside the parameters of proper medication use, the practice of doctor shopping could be curtailed. Our team of researchers wondered if HIT was currently being leveraged to control for doctor shopping, if there are public health benefits to doing so, and if other researchers had already identified this problem.
An internationally focused systematic review in 2019 examined the characteristics of doctor shoppers [7]. This review found 40% of 43 studies focused on opioids, antidepressants, or psychoactive drugs, and 60% surrounded chronic disease. Only 0.5% originated from the U.S., while 25% originated from Japan. Contributing behaviors to doctor shopping were comorbidities, active substance abuse, greater distance from healthcare facility, younger age, longer disease, and poor patient satisfaction. A U.S. focused review in 2018 examined the association between prescription drug monitoring programs (PDMP) and nonfatal and fatal drug overdoses [8]. It found 47% of the 17 articles implemented PDMP only, 12% implemented program features, and 41% implemented both. Low-strength evidence existed for an association between PDMP and fatal overdoses, and program features were strongly associated a decrease in overdose deaths. An EU focused review from 2012 examined misuse of medicines and mentions doctor shopping [9]. It listed opioids analgesics, methadone, buprenorphine, and z-drugs as the chief drugs misused. It also identified the international drug control system as a control for abuse.
The United Nations’ International Narcotics Control Board predicts that misuse of prescription drugs will exceed illicit drug use soon [10]. In 01 January 2013, Americans reported misuse or abuse of prescription painkillers and 17,000 American died of overdose from painkillers [11]. Prescription drug abuse in the U.S. is second only to marijuana use across all age groups and close to 1.4 million Germans are dependent on prescription drugs. Overdose deaths involving prescription opioids in the U.S. were five times higher in 2016 than in 1999 [12].
Our research investigates doctor shopping and the HIT tools available to address it. Properly designed, HIT enables healthcare providers and patients to electronically access systems, records, or shared information in order to improve quality, safety, and effective care [6]. An example is the prescription drug monitoring program (PDMP): an electronic database in the U.S. that tracks controlled substance prescriptions in a state [13]. Another example can be seen in a health information exchange (HIE): the mobilization of health care information electronically across organizations within a region, community, or hospital system [14]. Outside the U.S., PharmaCloud is a system that enables physicians at contracted medical services providers to search patients’ medication records over the previous three months to prevent drug shopping [15]. Lastly, smart cards (NHI-IC cards) carry information about a patient’s prescribed medications received from different hospitals nationwide. This system can address the problem of duplicate medications for outpatients visiting multiple hospitals [16].
In addition to the HIT solutions associated with doctor shopping, some key terms for this research include multiple provider episodes (MPE), which is the obtainment of controlled substances from some minimum number of prescribers and/or pharmacies in a given period of time [17]; nonmedical use of prescription medications (NMPM) is the use of medications without a prescription from a health care provider, use in a manner other than as directed [18]; and national provider identifier (NPI) is a unique 10-digit identification number issued to healthcare providers in the United States by the Centers for Medicare and Medicaid Services [19]. Our research investigates why doctor shopping is dangerous and how health outcomes affect patient populations. Identifying doctor shopper drug shopping patterns with the use of HIT should theoretically help providers better understand and control this phenomenon.

1.2. Objectives

The objective of this systematic review is to determine the prevalence of doctor shopping and how HIT can be useful in reducing it. Our research demonstrates that doctor shopping is an international concern where abuse and addiction of drugs is prevalent. The lack of an integrated health information exchange makes it difficult for providers to gain the needed information to address if an individual has already received a medication or service [14]. This review should help identify other means to control doctor shopping and their effectiveness through the examination of medical outcomes.

2. Materials and Methods

2.1. Protocol and Registration

This review followed the Kruse protocol published in 2019 [20]. It was reported in accordance with preferred reporting items for systematic reviews and meta-analysis (PRISMA) [21]. This review was registered with PROSPERO on 2 May 2020. In accordance with rules at PROSPERO, the registration was completed before analysis began.

2.2. Eligibility Criteria

Studies in this review were eligible if some form of HIT was implemented in the control of doctor shopping, they were published in quality journal (peer reviewed), and were published in the last 10 years. Preferably, these studies also reported medical outcomes, but that was not a requirement for selection. Moreover, 10 years was chosen as the time frame because in the realm of technology, 10 years is enough time to capture current trends without confounding the results with outdated technology, and because 10 years was used in the systematic reviews referenced in our introduction section. A quality assessment of articles was made with the Johns Hopkins nursing evidence-based practice rating scale (JHNEBP) [22].

2.3. Information Sources

Reviewers queried four databases: The Cumulative Index of Nursing and Allied Health Literature (CINAHL), PubMed (MEDLINE), Web of Science, and Embase (Science Direct). Databases were filtered for the last 10 years. Database searches occurred between 1–15 February 2020.

2.4. Search

Reviewers conducted a Google Scholar search using general terms about the topic. The 10 most recent articles were identified on the subject and reviewers collected the key terms from these studies to help form a Boolean search string. Using the PubMed Medical Subject Headings (MeSH), reviewers used the terms gathered from the 10 articles to examine how they were indexed and categorized. Once a Boolean search string was assembled, it was tested out several times in PubMed and customized for maximum, most effective yield. The final search string was (“doctor shopping” OR “drug shopping”) AND (“health information technology” OR “health information exchange” OR informatics). The same string was used for all four databases. Reviews were filtered out and other filters were used to help the search focus on quality articles on the subject.

2.5. Study Selection

Reviewers followed the Kruse Protocol for conducting a systematic review through the use of three consensus meetings [20]. Search results from the four databases were downloaded to a common Excel spreadsheet used as a literature matrix. This spreadsheet was used throughout the process to extract data and analyze results. This piloted form had several standard data fields to collect at each stage of the process. The group leader assigned workload so all abstracts were screened by at least two reviewers against the objective statement. Reviewers made independent recommendations to keep or discard using the following codes to document their work: D = Duplicate, NJ = non-journal, P = Protocol, B = Book, R = Review, M = Model, and NG = Not Germane. During the first consensus meeting, disagreement with recommendations was discussed. A tie was broken through a third reviewer’s assessment of the article’s applicability. By the end of the meeting, a final set of articles was identified to analyze. A kappa statistic was calculated from this process [23,24].

2.6. Data Collection Process

In preparation for the second consensus meeting, the group leader assigned workload to ensure all articles were analyzed by at least two reviewers. Reviewers read through articles twice: (1) to collect participants, intervention, comparison, outcome, and study design (PICOS) data and (2) to make observations relevant to the objective. During the second consensus meeting, reviewers discussed their observations. From the collective set of observations, a thematic analysis was performed to make sense of the data [25]. This served two purposes: (1) to make sense of the observations and (2) to find synergistic effects that result in “ah ha” moments when reviewers remember reading about a theme but did not record it fully. Reviewers then carefully read through the articles a third time to make more detailed observations relevant to the themes. During the third consensus meeting, inferences were made through observed interactions between the themes.

2.7. Data Items

Through the spreadsheet that served as a piloted form [20], standard data items were collected: participants, intervention (health information technology), study design, results compared to a control group (where applicable), facilitators and barriers to the use of health information technology, medical outcomes, sample size, bias within studies, effect size, country of origin, statistics used, a quality assessment from the JHNEBP [22], and general observations about the article that would help interpret the results.

2.8. Risk of Bias within and across Studies

Along the process of extracting data, general observations of bias and quality were made by each reviewer. Bias, such as selection bias, was discussed in the second consensus meeting. These were important to observe because bias can limit the external validity of the results from studies. Quality assessments from the JHNEBP were also discussed in the second consensus meeting. The JHNEBP has existed since 2007. It is comprised of five levels for strength of evidence and three levels for quality of evidence. The levels under strength of evidence are as follows: level 1 is an experimental study or randomized control trial (RCT); level 2 is quasi-experimental studies; level 3 is non-experimental, qualitative, or meta-synthesis studies; level 4 is opinion of nationally recognized experts based on research evidence or consensus panels; and level 5 is opinions of experts that is not based on research evidence. The levels under quality of evidence are as follows: A (high), B (good), or C (low quality or major flaws). Under each of these levels, specifics are defined for research, summative reviews, organizational, and expert opinion; e.g., research in level A must have consistent results with sufficient sample size, adequate control, and definitive conclusions; research in level B must have reasonably consistent results, sufficient sample size, some control, and definitive conclusions; research at level C has little evidence with inconsistent results, insufficient sample size, and conclusions that cannot be drawn from the data. Articles with a strength of evidence rating below Level 4 will be screened out. Quality of evidence below level B are highly suspect and must have full consensus of the group to be kept for analysis.

2.9. Summary Measures

The review analyzed studies with qualitative, quantitative, and mixed methods, so the summary measures sought were not consistent. The preferred summary statistic would be the risk ratio, but descriptive statistics, means’ comparisons (student-t) are also sufficient. Summary statistics were also discussed at the second consensus meeting.

2.10. Additional Analysis

At the second consensus meeting, a thematic analysis was performed to group observations into themes. These themes were measured across all articles analyzed and reported in summary statistics in a series of affinity matrices. The thematic analysis summarized themes for facilitators, barriers, and medical outcomes. These are reported in affinity matrices in the Results section.

3. Results

3.1. Study Selection

The study selection process performed is illustrated in Figure 1. A kappa statistic was calculated after the first consensus meeting (k = 0.95), which indicates near perfect agreement [23,24]. After screening, removing duplicates and assessing for eligibility, the 48 articles chosen for analysis came from CINAHL (1, 2%), Web of Science (1, 2%), PubMed (28, 58%), and Science Direct (18, 38%).

3.2. Study Characteristics

Using the piloted form, reviewers collected several standard items used for summary, such as PICOS. A PICOS table is provided in Table 1. Additional items were collected for analysis, such as forms of assistive technology interventions, facilitators, and barriers to the use of assistive technologies, and the medical outcomes observed from those older adults using assistive technology solutions. These are presented in Table 2. Table 1 and Table 2 lists articles in reverse chronological order: 2020 (1) [26], 2019 (7) [27,28,29,30,31,32,33], 2018 (4) [34,35,36,37], 2017 (3) [38,39,40], 2016 (7) [17,41,42,43,44,45,46], 2015 (4) [15,47,48,49], 2014 (3) [11,14,50], 2013 (2) [51,52], 2012 (4) [53,54,55,56], 2011 (6) [13,16,57,58,59,60], 2010 (1) [61].

3.3. Risk of Bias within Studies

Reviewers recorded observations of bias at the study level. The most common form of bias was convenience samples taken from one country only. This was common to every article in the review. This is logical since countries struggle enough with domestic interoperability. International interoperability may be too much to ask for in the near term. There was one instance of selection bias [40]. These examples of bias limit the external validity of the results.

3.4. Results of Individual Studies

Reviewers collected their observations of intervention and medical outcomes during the analysis phase. The narrative analysis of their observations identified themes. A summary of these themes is listed in Table 2. Repetition in the frame of a theme is due to multiple observations from the same article for that theme. For instance, the theme increased talking comprised observations of “increased utterances” and “increased sustained conversations.” A translation from observations to themes for interventions, medical outcomes, facilitators, and barriers are listed in Appendix A. Additional data items extracted are displayed in Appendix B: sample size, bias, country of origin, statistics, and quality assessments.

3.5. Synthesis of Results

This subsection addresses meta-analyses. This manuscript is a systematic review. This subsection will be deleted after the review process. It is included to reassure reviewers that we followed the PRISMA checklist.

3.6. Risk of Bias across Studies

Table 3 summarizes the quality indicators identified by the JHNEBP tool [22]. The most prevalent assessment in the strength of evidence (panel a) was level III, followed by IV, and II. For quality of evidence (panel b), the most frequently assessed level was level A, followed by B and C. It is certainly preferable for the strength of evidence be closer to level I, but that result did not materialize from the screening and selection process. This limitation will be addressed later.

3.7. Additional Analysis

3.7.1. Interventions of HIT

The results of consensus meeting three identified seven intervention themes that corresponded with utilizing HIT to control for doctor shopping. These are listed in Table 4. In the interest of brevity, only the top 90% are described. The intervention PDMP (state-run prescription drug monitoring program or interviews/surveys about PDMP) appeared in 15/42 articles (36%) [13,26,28,31,38,39,41,43,49,50,51,54,55,56,60]. These articles all originated from the United States because that is the only country that uses PDMP. The intervention national health system database (European, Scotland, French, Japan, Finland) appeared in 7/42 articles (17%) [17,36,37,42,44,53,61]. The intervention computer model (e.g., clustering models, PageRank, social network analysis) appeared in 5/42 articles (17%) [29,30,32,46,59]. Three of these articles originated from the United States, while the others were from Japan and France. The intervention combination (PDMP combined with worker’s compensation claims, PDMP and Lock-in programs, PDMP education efforts and pharmacist panels, PDMP and PBM, Computerized Provider Order Entry (CPOE) and NHI-IC cards) appeared in 5/42 articles (17%) [11,16,27,34,54]. Four of these articles originated in the United States, while the other was from Taiwan. The intervention other (pharmacological database, medication record sharing program, PharmaCloud, ACOS and DAWN, and CEIP) appeared in 5/42 articles (17%) [15,33,35,52,57]. Two of these articles originated from the United States, two from Taiwan, and one from France.

3.7.2. Facilitators of HIT

The results of consensus meeting three identified five themes and two individual observations that corresponded with facilitators of HIT to control for doctor shopping. These are listed in Table 5, which contains Table 5, Table 6 and Table 7 (facilitators, barriers, and medical outcomes). In the interest of brevity, only the first 75% will be listed (other than not reported). The facilitator theme was government support (state supports prescription monitoring or prescription monitoring programs) occurred in 31/52 occurrences (60%) [13,14,17,27,28,31,33,35,36,37,39,40,41,42,43,44,45,47,48,49,52,53,54,55,56,57,58,59,60,61]. In total, 17 of these articles originated from the United States, seven from France, three from Taiwan, while the others were from original originations in Finland and Scotland. The theme prescriber support (physician, nurse practitioner) occurred 6/52 times (12%) [28,31,45,55,56]. Four of these articles originated from the United States while the other was from Taiwan.

3.7.3. Barriers of HIT

The results of the consensus meeting identified three themes and six individual observations that corresponded with barriers of HIT to control for doctor shopping. These are listed in Table 6. In the interest of brevity, only the themes will be discussed (other than not reported). The theme of data sharing (PDMP do not all share across state lines) occurred in 5/52 occurrences (10%) [11,27,39,45,51]. These articles all originated from the United States. The theme access not mandatory (access to PDMP or PharmaCloud not mandatory and the intervention is not widely implemented because of this fact) occurred in 4/52 occurrences (8%) [15,28,34,49]. Three of these articles originated from the United States while the other originated from Taiwan. The theme participation was not mandatory (not all states participate in health information exchanges, not all facilities participate in PharmaCloud) occurred in 3/52 occurrences (6%) [15,16,58]. Two of these articles originated in Taiwan, while the other was from the United States.

3.7.4. Medical Outcomes Commensurate with HIT as Intervention

The results of consensus meeting three identified two themes and four individual observations that corresponded with medical outcomes commensurate with HIT to control for doctor shopping. These are listed in Table 7. In the interest of brevity, only the themes will be listed (other than not reported). The theme reduced [doctor] shopping (decreased shopping and diversion) occurred in 3/42 articles (7%) [50,51,55]. These originated from the United States. The theme reduced mortality (decline in overdose mortality) occurred in 2/42 articles (5%) [34,40]. These originated from the United States.

3.8. Interactions between Observations

The intervention of the national health system database resulted in seven instances of government support [17,36,37,42,44,53,61]. The intervention of the computer model resulted in five instances of simple to implement [29,30,32,46,59]. The intervention PDMP resulted in two instances of access not mandatory [28,49] and two instances of data sharing [39,51].

4. Discussion

4.1. Summary of Evidence

Through the analysis of 42 articles, this review identified seven interventions, five facilitator themes with two individual observations, three barrier themes with six individual observations, and two medical outcome themes with four individual observations. Most of the articles analyzed were non-experimental (28/42, 67%) but of high quality (25/42, 60%). The facilitator themes mentioned most frequently were government support (31/52, 60%) [13,14,17,27,28,31,33,35,36,37,39,40,41,42,43,44,45,47,48,49,52,53,54,55,56,57,58,59,60,61] and prescriber support (5/52, 12%) [28,31,45,55,56]. The barrier themes mentioned most frequently were data sharing (5/48, 10%) [11,27,39,45,51] and access not mandatory (4/48, 8%) [15,28,34,49]. The medical outcome themes mentioned most frequently were reduced shopping (3/42, 7%) [50,51,55] and reduced mortality (2/42, 5%) [34,40]. A large majority originated from the United States (26/42, 62%), but also from France (7/42, 17%), Taiwan (5/42, 12%), Japan (2/42, 5%), and one each from Finland and Scotland.
The high level of government and prescriber support was reassuring to observe because it indicates that government health agencies recognize the problem of doctor shopping and are attempting to address it through regulation. It also indicates that governments and prescribers are communicating about the problem and collaborating for solutions. This result was expected because they had been observed in other research [7,8,9].
One interesting dichotomy was observed. In medical outcomes, 2/42 articles mentioned a reduction in overdose mortality commensurate with the use of HIT measures to control for doctor shopping [34,40], while one listed no decline in mortality [54]. A key point made by one article is that the control programs like PDMP do nothing to treat the disease of addiction driving the behavior [34]. This author mentioned that unless control programs institute treatment [26], doctor shoppers will find other means of finding their illicit drugs to misuse.
Policy makers should examine the barriers listed in this review. The barrier of data access predominantly spoke of the United States with state-run PDMPs. All but three states share data, but Florida, Georgia, and Nebraska do not allow data sharing [49]. Without nationwide data sharing agreements, shoppers just travel to the next state to do their shopping. Shoppers are documented to travel an average of 199.5 miles to shop, while non-shoppers do not travel at all [51]. Another key barrier is that participation is not mandatory. This occurred in the he U.S. with PDMP and Taiwan with PharmaCloud. If participation is not mandatory, universal enforcement cannot occur.

4.2. Limitations

The researchers analyzed articles from 2010 to 2020. The reviewers hoped to find higher strength studies from which to extract data and summarize results. However, there is a paucity of high-strength studies in this area. Future researchers should consider this high-need area to explore.
This review limited its search to four databases: PubMed, CINAHL, Science Direct, and Web of Science. It did not include broader sources such as Google Scholar. Even though 42 articles were analyzed, it is possible other sources may have yielded higher strength articles to include in the analysis. Only 67% were high quality articles, while the others (17) were of good or low quality. It is important to base conclusions on high quality articles, but often we are relegated to what is already published.
A team of reviewers determined the articles to be included in the study. This was also done to mitigate the risk of selection bias. The risk of this practice, however, is that the team may have differed in their selection process. To mitigate this risk, researchers held consensus meetings and identified the research objective, and had multiple reviews for each article. The limitation is that there may not have been enough consensus meetings. The kappa statistic shows the consensus meetings were effective, yet a stronger level of agreement is possible.

5. Conclusions

This research supports the use of HIT as a control for doctor shopping. Computer models are simple to implement and monitoring systems exist to help prescribers and dispensers’ control for doctor shopping behavior. Greater interaction, whether voluntary or mandatory, yields greater success as the behavior is identified. After identifying the behavior, treatment and help should follow. Otherwise, the patient will find other outlets for the behavior. Government intervention is evident in the research, and this enabler should be exploited. Robust data sharing and both participation and consultation of PDMP should be a standard in the industry to decrease doctor shopping and improve mortality.

Author Contributions

B.K. served as the project leader who analyzed 30% of the articles; G.G. served as the graphic artists who analyzed 30% of the articles; K.C. served as the literature matrix manager who analyzed 30% of the articles; S.B. served as the junior editor who analyzed 30% of the articles; C.S.K. served as the senior editor who analyzed 100% of the articles and repackaged the manuscript for publication. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

CEIPFrench Centers for Evaluation and Information on Pharmacodependence
CNCPChronic non-cancer pain
DSIDrug Shopping Indicator
HIEHealth Information Exchange
NPINational provider identifier
MMEmorphine milligram equivalents
NMPRNonmedical prescription use
PBMPharmacy Benefit Managers
PDMRPrescription Drug Monitoring Program
SNIIRAMGlobal health insurance reimbursement database

Appendix A

Table A1. Map of Observations to Themes.
Table A1. Map of Observations to Themes.
AuthorsInterventionIntervention ThemeMedical Outcomes ReportedOutcome ThemeFacilitatorsFacilitator ThemeBarriersBarrier Theme
Pett RG, et al.PDMPPDMPNaloxone prescribed to shoppersShoppers prescribed treatmentPharmacists support PDMPPharmacists supportNot reportedNot reported
Durand Z, et al.PDMP and worker’s compensation claimsCombinationNot reportedNot reportedGovernment support for PDMPGovernment supportPDMP systems do not share data across state linesData sharing
Freeman PR, et al.Interviews about PDMPPDMPNot reportedNot reportedGovernment support for PDMP, Pharmacists support for PDMP, PCP support for PDMPGovernment supportAccess not mandatoryAccess not mandatory
Pharmacists support
Prescriber support
Nagarajan R and Talbert Jcomputer modelComputer modelNot reportedNot reportedModel only requires data and a statisticianSimple to implementNot reportedNot reported
Perry BL, et al.computer model PageRankComputer modelNot reportedNot reportedNot reportedNot reportedNot reportedNot reported
Soffin EM, et al.PDMPPDMPAccessing real-time information about patients’ prescription opioid status using PDMP reduces opioid quantities prescribedReduced opioids prescribedState supports PDMP, Providers support PDMPGovernment supportNot reportedNot reported
Prescriber support
Stopka TJ, et al.computer modelComputer modelNot reportedNot reportedComputer model not difficult to implement (low cost)Simple to implementNot reportedNot reported
Wang Y, et al.Pharmacological databaseOtherNot reportedNot reportedState supports prescription monitoringGovernment supportNot reportedNot reported
Butler JM, et al.PDMP, Lock-in programsCombinationBroader range of drug schedules and an increases frequency of updating the PDMP results in lower opioid-related mortalityReduced mortalityA “must use” law (ten states) significantly decreased doctor shoppingMust use lawPDMP is not mandatory, Lock-in programs do not treat substance abuse (may just drive users to black-market) Only billing information is used (not cash)Access not mandatory
Does not treat addiction
Lin JH, et al.Medication record sharing programOtherNot reportedNot reportedGovernment support for the medication record sharing programGovernment supportNot reportedNot reported
Ponte C, et al.SNIIRAM databaseNational health system DBNot reportedNot reportedGovernment support for prescription monitoringGovernment supportNot reportedNot reported
Torrance N, et al.NHS and Generation Scotland databases combined to identify trendsNational health system DBNot reportedNot reportedState supports prescription monitoringGovernment supportNot reportedNot reported
Ali MM, et al.Survey instrument to assess effectiveness of the PDMPPDMP10–20 fewer days of NMPR use.Fewer days of useNot reportedNot reportedNot reportedNot reported
Rutkow L, et al.PDMPPDMPNot reportedNot reportedGovernment support for prescription monitoringGovernment supportPDMP systems do not share data across state linesData sharing
Simeone RPDMP, education efforts, pharmacy panels that span the countryCombinationDecline in overdose mortalityReduced mortalityGovernment support for PDMP, Pharmacy groups have designed a proprietary system to track prescriptionsGovernment supportEnterprising dealers can use more drug collection agentsEasily thwarted
Pharmacists support
Chenaf C, et al.French national health systemNational health system DBNot reportedNot reportedFrench national health system monitors drug useGovernment supportNot reportedNot reported
Delorme J, et al.French national health systemNational health system DBNot reportedNot reportedFrench national health system monitors drug useGovernment supportNot reportedNot reported
Kea B, et al.PDMPPDMPNot reportedNot reportedGovernment support for PDMPGovernment supportNot reportedNot reported
National Council of State Boards of NursingPDMPPDMPNot reportedNot reportedGovernment support for PDMPGovernment supportNot reportedNot reported
Okumura Y, et al.Japan national health databaseNational health system DBNot reportedNot reportedGovernment support for monitoring programGovernment supportNot reportedNot reported
Ong MS, et al.Provider patient-sharing networksHealth insurance claimsNot reportedNot reportedState supports PDMP, Providers support PDMPGovernment supportState PDMPs cannot share data across state linesData sharing
Prescriber support
Takahashi Y, et al.Social network analysisComputer modelNot reportedNot reportedSocial network analysis is not difficult to implement (low cost)Simple to implementNot reportedNot reported
Huang SK, et al.PharmaCloudOtherNot reportedNot reportedThe drug expense per person declined (2–5%), Government support for PharmaCloudCost savingsIntervention is not widely adopted and not mandatoryParticipation not mandatory
Government supportAccess not mandatory
Lin MH, et al.Medication record sharing programHealth insurance claimsNot reportedNot reportedGovernment support for the medication record sharing programGovernment supportNot reportedNot reported
Lu TH, et al.Medication record sharing programHealth insurance claimsNot reportedNot reportedGovernment support for the medication record sharing programGovernment supportNot reportedNot reported
Webster LR and Grabois MPDMPPDMPNot reportedNot reportedState supports prescription monitoringGovernment supportAccess to PDMP not mandatoryAccess not mandatory
Han H, et al.PDMPPDMPprior to the PDMP in California, the prevalence of schedule II opioid users in California increased by 150%–280% and prevalence of doctor shoppers increased 111%–213% over 9 years.Reduced shoppingNot reportedNot reportedNot reportedNot reported
Hypponen H, et al.HIEHealth information exchangeNot reportedNot reportedGovernment support for the HIE, Decrease in healthcare costs through reduced duplicate testing, Increased efficiency of clinical information gatheringGovernment supportNot reportedNot reported
Cost savings
Increased efficiency
Shepherd JPDMP and PBMCombinationNot reportedNot reportedNot reportedNot reportedInadequate data collection, PBM do not process all painkiller prescriptions,Inadequate data collection
Ineffective utilization of data,Ineffective data use
Insufficient interstate data sharing,Data sharing
Constraints on data sharing with law enforcement and state agencies,Constraints on enforcement
Prescription drugs purchased with cash (not insurance) not processed through PBMCash-only not captured
Cepeda MS, et al.PDMPPDMPShopping decreased within the same state,Reduced shoppingNot reportedNot reportedPDMP systems do not share data across state linesData sharing
Modarai F, et al.Automation of Reports and Consolidation Orders System (ARCOS),
Drug Abuse Reporting Network (DAWN)
OtherNot reportedNot reportedGovernment support for ARCOS and DAWNGovernment supportNot reportedNot reported
Rouby F, et al.Reimbursement databaseNational health system DBNot reportedNot reportedGovernment support for prescription monitoringGovernment supportNot reportedNot reported
Simoni-Wastila and Qian JPDMPPDMPNo decline in overdose mortalityNo decline in mortalityState and federal government support for PDMPGovernment supportNot reportedNot reported
Worley J, et al.PDMPPDMPPDMPs decrease diversion and doctor shoppingReduced shoppingState supports PDMP,Government supportNot reportedNot reported
Providers support PDMPPrescriber support
Worley J, et al.PDMPPDMPNot reportedNot reportedState supports PDMP,Government supportNot reportedNot reported
Providers support PDMPPrescriber support
Fass JA and Hardigan PCPDMPPDMPNot reportedNot reportedGovernment support for PDMPGovernment supportNot reportedNot reported
Frauger E, et al.CEIPOtherNot reportedNot reportedGovernment support for CEIPGovernment supportNot reportedNot reported
Hincapie AL, et al.Interviews about HIEHealth information exchangeNot reportedNot reportedGovernment support for HIEGovernment supportNot all participate in the HIE, therefore data cannot be universally exchangedParticipation not mandatory
Hsu MH, et al.CPOE and NHI-IC cardsCombinationNot reportedNot reportedPhysicians accept the interventionPrescriber supportParticipation is not universal or mandatoryParticipation not mandatory
Pauly V, et al.computer modelComputer modelNot reportedNot reportedGovernment supports prescription monitoringGovernment supportNot reportedNot reported
Wilsey BL, et al.PDMPPDMPNot reportedNot reportedState supports prescription monitoringGovernment supportNot reportedNot reported
Pradel V, et al.Prescription databaseNational health system DBNot reportedNot reportedGovernment support for prescription monitoringGovernment supportNot reportedNot reported

Appendix B

Table A2. Sample Size, Bias, Country of Origin, Statistics, and Quality Assessment.
Table A2. Sample Size, Bias, Country of Origin, Statistics, and Quality Assessment.
AuthorsSample SizeBias within StudyCountry of OriginStatistics UsedJHNEBP
StrengthQuality
Pett RG, et al.967, average age not reportedUnited States onlyUnited StatesLogistic regressionIIA
Durand Z, et al.172,256, average age 41United States onlyUnited Statest-testIIIA
Freeman PR, et al.48 PCP, 60 pharmacists, average age not reportedUnited States onlyUnited Statesn/aIIIB
Nagarajan R and Talbert J11,596United States onlyUnited StatesTukey’s outlier detection and surrogate testingIIIB
Perry BL, et al.526,914 patients, 2,107,656 quarterly prescription entriesUnited States onlyUnited StatesRegressionIIIA
Soffin EM, et al.n/aUnited States onlyUnited Statesn/aIVC
Stopka TJ, et al.3,143,817, average age not reportedUnited States onlyUnited Statest-testIVC
Wang Y, et al.17,000, average age not reportedUnited States onlyUnited Statest-test and descriptivesIIIA
Butler JM, et al.n/aUnited States onlyUnited Statesn/aIVB
Lin JH, et al.106,508, average age not reportedTaiwan onlyTaiwanRegressionIIA
Ponte C, et al.11.7 millionFrance onlyFrancet-testIIIA
Torrance N, et al.1,036,446, average age not reportedScotland onlyScotlandChi squaredIIIA
Ali MM, et al., average age not reportedUnited States onlyUnited StatesLogit regressionIIIA
Rutkow L, et al.37, average age not reportedUnited States onlyUnited Stateslanguage processingIIIB
Simeone R11 billionUnited States Only,
Selection bias because pharmacies involved in illicit activity are not going to provide data
United Statest-testIIIA
Chenaf C, et al.3505, average age not reportedFrance onlyFranceCox proportional hazard modelIIIA
Delorme J, et al.2043France onlyFranceCox proportional hazard modelIIIA
Kea B, et al.139,256, average age not reportedUnited States onlyUnited Statesdescriptives and natural language processingIIIB
National Council of State Boards of Nursingn/aUnited States onlyUnited Statesn/aIVB
Okumura Y, et al.1,178,361, average age not reportedJapan onlyJapant-testIIIA
Ong MS, et al.5659 patients and 1448 provider pairsUnited States onlyUnited StatesLogistic regressionIIIA
Takahashi Y, et al.1.24 million, average age not reportedJapan onlyJapanregressionIIIA
Huang SK, et al.30,000 physicians at 1898 facilitiesTaiwan onlyTaiwannatural language processingIIIA
Lin MH, et al.32,813,217 visits, average age not reportedTaiwan onlyTaiwandescriptives and natural language processingIIA
Lu TH, et al.6947, average age not reportedTaiwan onlyTaiwandescriptives and natural language processingIIA
Webster LR and Grabois Mn/aUnited States onlyUnited Statesn/aIVC
Han H, et al.3,260,824, average age not reportedUnited States onlyUnited Statesn/aIIIB
Hypponen H, et al.1693, average age not reportedFinland onlyFinlandnatural language processingIIIA
Shepherd Jn/aUnited States onlyUnited Statesn/aIVA
Cepeda MS, et al.10,910,451, average age 45United States onlyUnited Statest-testIIIA
Modarai F, et al. United States onlyUnited StatesRegression, spatial cluster analysisIIIB
Rouby F, et al.4.5 millionFrance onlyFrancet-testIIIA
Simoni-Wastila and Qian J2,175,012, average age not reportedUnited States onlyUnited Statesmultinomial regressionsIIIA
Worley J, et al.n/aUnited States onlyUnited Statesn/aIVC
Worley J, et al.n/aUnited States onlyUnited Statesn/aIVC
Fass JA and Hardigan PC836, average age not reportedUnited States onlyUnited Stateslanguage processingIIIA
Frauger E, et al.n/aFrance onlyFrancen/aIVB
Hincapie AL, et al.34, average age not reportedUnited States onlyUnited Stateslanguage processingIIIB
Hsu MH, et al.8, average age 47.9, 88% maleTaiwan onlyTaiwanChi-squared and two-sided z-tests with Bonferroni adjustmentsIIIB
Pauly V, et al.4787 patients, average age 37.6France onlyFranceClusteringIIIA
Wilsey BL, et al.2,849,464 patients, average age of shoppers 50.7United States onlyUnited StatesRegressionIVC
Pradel V, et al.128,000, average age not reportedFrance onlyFrancet-testIIIA

References

  1. Kieffer, C.H. Citizen empowerment: A developmental perspective. Prev. Hum. Serv. 1984, 3, 9–36. [Google Scholar] [CrossRef]
  2. Castro, E.M.; Van Regenmortel, T.; Vanhaecht, K.; Sermeus, W.; Van Hecke, A. Patient empowerment, patient participation and patient-centeredness in hospital care: A concept analysis based on a literature review. Patient Educ. Couns. 2016, 99, 1923–1939. [Google Scholar] [CrossRef] [PubMed]
  3. World Health Organization. Global Status Report on Noncommunicable Diseases 2014; World Health Organization: Geneva, Switzerland, 2014; ISBN 978 92 4 156485 4. [Google Scholar]
  4. Schneberk, T.; Raffetto, B.; Friedman, J.; Wilson, A.; Kim, D.; Schriger, D.L. Opioid prescription patterns among patients who doctor shop; Implications for providers. PLoS ONE 2020, 15. [Google Scholar] [CrossRef] [PubMed]
  5. Balazote, P.S.; Sicilia, M.-A. Interoperability in Healthcare Information Systems: Standards, Management, and Technology; IGI Global: Hershey, PA, USA, 2013. [Google Scholar]
  6. What Is Interoperability. Available online: https://www.healthit.gov/topic/interoperability (accessed on 11 July 2020).
  7. Biernikiewicz, M.; Taieb, V.; Toumi, M. Characteristics of doctor-shoppers: A systematic literature review. J. Mark. Access Health Policy 2019, 7. [Google Scholar] [CrossRef] [Green Version]
  8. Fink, D.; Schleimer, J.; Sarvet, A.; Grover, K.; Delcher, C.; Castillo-Carniglia, A.; Kim, J.; Rivera-Aguirre, A.; Henry, S.; Martins, S.; et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: A systematic review. Ann. Intern. Med. 2018, 168, 783–790. [Google Scholar] [CrossRef]
  9. Casati, A.; Sedefov, R.; Pfeiffer-Gerschel, T. Misuse of medicines in the European union: A systematic review of the literature. Eur. Addict. Res. 2012, 18, 228. [Google Scholar] [CrossRef]
  10. Report of the International Narcotics Control Board for 2007. Available online: https://www.incb.org/incb/en/publications/annual-reports/annual-report-2007.html (accessed on 11 July 2020).
  11. Shepherd, J. Combating the prescription painkiller epidemic: A national prescription drug reporting program. Am. J. Law Med. 2014, 40, 85–112. [Google Scholar] [CrossRef]
  12. CDC. Prescription Opiod Data. Available online: https://www.cdc.gov/drugoverdose/data/prescribing.html (accessed on 11 July 2020).
  13. Fass, J.A.; Hardigan, P.C. Attitudes of florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances. J. Manag. Care Pharm. 2011, 17, 430–438. [Google Scholar] [CrossRef]
  14. Hyppönen, H.; Reponen, J.; Lääveri, T.; Kaipio, J. User experiences with different regional health information exchange systems in Finland. Int. J. Med. Inform. 2014, 83, 1–18. [Google Scholar] [CrossRef]
  15. Huang, S.-K.; Wang, P.-J.; Tseng, W.-F.; Syu, F.-K.; Lee, M.-C.; Shih, R.-L.; Sheen, M.-T.; Chen, M.S. NHI-PharmaCloud in Taiwan—A preliminary evaluation using the RE-AIM framework and lessons learned. Int. J. Med. Inform. 2015, 84, 817–825. [Google Scholar] [CrossRef]
  16. Hsu, M.-H.; Yeh, Y.-T.; Chen, C.-Y.; Liu, C.-H.; Liu, C.-T. Online detection of potential duplicate medications and changes of physician behavior for outpatients visiting multiple hospitals using national health insurance smart cards in Taiwan. Int. J. Med. Inform. 2011, 80, 181–189. [Google Scholar] [CrossRef] [PubMed]
  17. Chenaf, C.; Kabore, J.L.; Delorme, J.; Roche, L.; Eschalier, A.; Delage, N.; Authier, N.; Pereira, B.; Mulliez, A. Incidence of tramadol shopping behavior in a retrospective cohort of chronic non-cancer pain patients in France. Pharmacoepidemiol. Drug Saf. 2016, 25, 1088–1098. [Google Scholar] [CrossRef] [PubMed]
  18. Popovici, I.; Hijazi, B.; Maclean, J.C.; Radakrishnan, S. The effect of state laws designed to prevent nonmedical prescription opioid use on overdose deaths and treatment. Health Econ. 2018, 27, 294–305. [Google Scholar] [CrossRef] [PubMed]
  19. HHS. NPI: What You Need to Know; Centers for Medicare and Medicaid Services: Baltimore, MD, USA, 2016; p. 10. [Google Scholar]
  20. Kruse, C.S. Writing a systematic review for publication in a health-related degree program. JMIR Res. Protoc. 2019, 8, e15490. [Google Scholar] [CrossRef] [PubMed]
  21. David, M.; Alessandro, L.; Jennifer, T.; Douglas, G.A. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ Br. Med. J. 2009, 339, 332. [Google Scholar]
  22. Newhouse, R.; Dearbolt, S.; Poe, S.; Pugh, L.C.; White, K. JHNEBP evidence rating scales. In The Johns Hopkins Nursing Evidence-Based Practice Rating Scale; Centers for Medicare and Medicaid Services: Baltimore, MD, USA, 2005. [Google Scholar]
  23. Light, R.J. Measures of response agreement for qualitative data: Some generalizations and alternatives. Psychol. Bull. 1971, 76, 365. [Google Scholar] [CrossRef]
  24. McHugh, M.L. Interrater reliability: The kappa statistic. Biochem. Med. 2012, 22, 276–282. [Google Scholar] [CrossRef]
  25. Braun, V.; Clarke, V. Using thematic analysis in psychology. Qual. Res. Psychol. 2006, 3, 77–101. [Google Scholar] [CrossRef] [Green Version]
  26. Pett, R.G.; Mancl, L.; Revere, D.; Stergachis, A. Prescription drug monitoring program use and utility by Washington State pharmacists: A mixed-methods study. J. Am. Pharm. Assoc. 2020, 60, 57–65. [Google Scholar] [CrossRef] [Green Version]
  27. Durand, Z.; Nechuta, S.; Krishnaswami, S.; Hurwitz, E.L.; McPheeters, M. Prescription opioid use by injured workers in Tennessee: A descriptive study using linked statewide databases. Ann. Epidemiol. 2019, 32, 7–13. [Google Scholar] [CrossRef]
  28. Freeman, P.R.; Curran, G.M.; Drummond, K.L.; Martin, B.C.; Teeter, B.S.; Bradley, K.; Schoenberg, N.; Edlund, M.J. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. Res. Soc. Adm. Pharm. 2019, 15, 754–760. [Google Scholar] [CrossRef] [PubMed]
  29. Nagarajan, R.; Talbert, J. Network abstractions of prescription patterns in a medicaid population. Amia Jt. Summits Transl. Sci. Proc. 2019, 2019, 524–532. [Google Scholar]
  30. Perry, B.L.; Yang, K.C.; Kaminski, P.; Odabas, M.; Park, J.; Martel, M.; Oser, C.B.; Freeman, P.R.; Ahn, Y.Y.; Talbert, J. Co-prescription network reveals social dynamics of opioid doctor shopping. PLoS ONE 2019, 14, e0223849. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Soffin, E.M.; Lee, B.H.; Kumar, K.K.; Wu, C.L. The prescription opioid crisis: Role of the anaesthesiologist in reducing opioid use and misuse. Br. J. Anaesth. 2019, 122, e198–e208. [Google Scholar] [CrossRef] [PubMed]
  32. Stopka, T.J.; Amaravadi, H.; Kaplan, A.R.; Hoh, R.; Bernson, D.; Chui, K.K.H.; Land, T.; Walley, A.Y.; LaRochelle, M.R.; Rose, A.J. Opioid overdose deaths and potentially inappropriate opioid prescribing practices (PIP): A spatial epidemiological study. Int. J. Drug Policy 2019, 68, 37–45. [Google Scholar] [CrossRef]
  33. Wang, Y.; Delcher, C.; Li, Y.; Goldberger, B.A.; Reisfield, G.M. Overlapping prescriptions of opioids, benzodiazepines, and carisoprodol: “Holy Trinity” prescribing in the state of Florida. Drug Alcohol Depend. 2019, 205, 107693. [Google Scholar] [CrossRef]
  34. Butler, J.M.; Becker, W.C.; Humphreys, K. Big data and the opioid crisis: Balancing patient privacy with public health. J. Law Med. Ethics 2018, 46, 440–453. [Google Scholar] [CrossRef]
  35. Lin, J.-H.; Cheng, S.-H. The impact of a medication record sharing program among diabetes patients under a single-payer system: The role of inquiry rate. Int. J. Med. Inform. 2018, 116, 18–23. [Google Scholar] [CrossRef]
  36. Ponté, C.; Lepelley, M.; Boucherie, Q.; Mallaret, M.; Lapeyre Mestre, M.; Pradel, V.; Micallef, J. Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug Alcohol Depend. 2018, 187, 88–94. [Google Scholar] [CrossRef]
  37. Torrance, N.; Mansoor, R.; Wang, H.; Gilbert, S.; Macfarlane, G.J.; Serpell, M.; Baldacchino, A.; Hales, T.G.; Donnan, P.; Wyper, G.; et al. Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: A primary care data linkage study. Br. J. Anaesth. 2018, 120, 1345–1355. [Google Scholar] [CrossRef] [Green Version]
  38. Ali, M.M.; Dowd, W.N.; Classen, T.; Mutter, R.; Novak, S.P. Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health. Addict. Behav. 2017, 69, 65–77. [Google Scholar] [CrossRef] [PubMed]
  39. Rutkow, L.; Smith, K.C.; Lai, A.Y.; Vernick, J.S.; Davis, C.S.; Alexander, G.C. Prescription drug monitoring program design and function: A qualitative analysis. Drug Alcohol Depend. 2017, 180, 395–400. [Google Scholar] [CrossRef]
  40. Simeone, R. Doctor shopping behavior and the diversion of prescription opioids. Subst. Abus. Res. Treat. 2017, 11, 1–10. [Google Scholar] [CrossRef]
  41. National Council of State Boards of Nursing. A changing environment: 2016 NCSBN environmental scan. J. Nurs. Regul. 2016, 6, 4–37. [Google Scholar] [CrossRef]
  42. Delorme, J.; Chenaf, C.; Kabore, J.L.; Pereira, B.; Mulliez, A.; Tremey, A.; Brousse, G.; Zenut, M.; Laporte, C.; Authier, N. Incidence of high dosage buprenorphine and methadone shopping behavior in a retrospective cohort of opioid-maintained patients in France. Drug Alcohol Depend. 2016, 162, 99–106. [Google Scholar] [CrossRef] [PubMed]
  43. Kea, B.; Fu, R.; Lowe, R.A.; Sun, B.C. Interpreting the national hospital ambulatory medical care survey: United States emergency department opioid prescribing, 2006–2010. Acad. Emerg. Med. 2016, 23, 159–165. [Google Scholar] [CrossRef] [Green Version]
  44. Okumura, Y.; Shimizu, S.; Matsumoto, T. Prevalence, prescribed quantities, and trajectory of multiple prescriber episodes for benzodiazepines: A 2-year cohort study. Drug Alcohol Depend. 2016, 158, 118–125. [Google Scholar] [CrossRef] [PubMed]
  45. Ong, M.S.; Olson, K.L.; Cami, A.; Liu, C.; Tian, F.; Selvam, N.; Mandl, K.D. Provider patient-sharing networks and multiple-provider prescribing of benzodiazepines. J. Gen. Intern. Med. 2016, 31, 164–171. [Google Scholar] [CrossRef]
  46. Takahashi, Y.; Ishizaki, T.; Nakayama, T.; Kawachi, I. Social network analysis of duplicative prescriptions: One-month analysis of medical facilities in Japan. Health Policy 2016, 120, 334–341. [Google Scholar] [CrossRef] [PubMed]
  47. Lin, M.H.; Chang, H.T.; Tu, C.Y.; Chen, T.J.; Hwang, S.J. Doctor-shopping behaviors among traditional chinese medicine users in Taiwan. Int. J. Environ. Res. Public Health 2015, 12, 9237–9247. [Google Scholar] [CrossRef] [PubMed]
  48. Lu, T.H.; Lee, Y.Y.; Lee, H.C.; Lin, Y.M. Doctor shopping behavior for zolpidem among insomnia patients in taiwan: A nationwide population-based study. Sleep 2015, 38, 1039–1044. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Webster, L.R.; Grabois, M. Current regulations related to opioid prescribing. PM&R 2015, 7, S236–S247. [Google Scholar] [CrossRef]
  50. Han, H.; Kass, P.H.; Wilsey, B.L.; Li, C.S. Increasing trends in Schedule II opioid use and doctor shopping during 1999–2007 in California. Pharmacoepidemiol. Drug Saf. 2014, 23, 26–35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Cepeda, M.S.; Fife, D.; Yuan, Y.; Mastrogiovanni, G. Distance traveled and frequency of interstate opioid dispensing in opioid shoppers and nonshoppers. J. Pain 2013, 14, 1158–1161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Modarai, F.; Mack, K.; Hicks, P.; Benoit, S.; Park, S.; Jones, C.; Proescholdbell, S.; Ising, A.; Paulozzi, L. Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend. 2013, 132, 81–86. [Google Scholar] [CrossRef]
  53. Rouby, F.; Pradel, V.; Frauger, E.; Pauly, V.; Natali, F.; Reggio, P.; Thirion, X.; Micallef, J. Assessment of abuse of tianeptine from a reimbursement database using ‘doctor-shopping’ as an indicator. Fundam. Clin. Pharm. 2012, 26, 286–294. [Google Scholar] [CrossRef]
  54. Simoni-Wastila, L.; Qian, J. Influence of prescription monitoring programs on analgesic utilization by an insured retiree population. Pharmacoepidemiol. Drug Saf. 2012, 21, 1261–1268. [Google Scholar] [CrossRef]
  55. Worley, J. Prescription drug monitoring programs, a response to doctor shopping: Purpose, effectiveness, and directions for future research. Issues Ment. Health Nurs. 2012, 33, 319–328. [Google Scholar] [CrossRef]
  56. Worley, J. Psychiatric nursing’s role in preventing doctor shopping. J. Psychosoc. Nurs. Ment. Health Serv. 2012, 50, 4–5. [Google Scholar] [CrossRef]
  57. Frauger, E.; Pauly, V.; Pradel, V.; Rouby, F.; Arditti, J.; Thirion, X.; Lapeyre Mestre, M.; Micallef, J. Evidence of clonazepam abuse liability: Results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. Fundam. Clin. Pharm. 2011, 25, 633–641. [Google Scholar] [CrossRef]
  58. Hincapie, A.L.; Warholak, T.L.; Murcko, A.C.; Slack, M.; Malone, D.C. Physicians’ opinions of a health information exchange. J. Am. Med. Inf. Assoc. 2011, 18, 60–65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Pauly, V.; Frauger, E.; Pradel, V.; Rouby, F.; Berbis, J.; Natali, F.; Reggio, P.; Coudert, H.; Micallef, J.; Thirion, X. Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling high dosage Buprenorphine abuse. Drug Alcohol Depend. 2011, 113, 29–36. [Google Scholar] [CrossRef]
  60. Wilsey, B.L.; Fishman, S.M.; Gilson, A.M.; Casamalhuapa, C.; Baxi, H.; Lin, T.C.; Li, C.S. An analysis of the number of multiple prescribers for opioids utilizing data from the California Prescription Monitoring Program. Pharmacoepidemiol. Drug Saf. 2011, 20, 1262–1268. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Pradel, V.; Delga, C.; Rouby, F.; Micallef, J.; Lapeyre-Mestre, M. Assessment of abuse potential of benzodiazepines from a prescription database using ‘doctor shopping’ as an indicator. CNS Drugs 2010, 24, 611. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) figure that demonstrates the study selection process.
Figure 1. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) figure that demonstrates the study selection process.
Healthcare 08 00306 g001
Table 1. PICOS for all articles analyzed.
Table 1. PICOS for all articles analyzed.
AuthorsParticipantsInterventionResults (Compared to Control Group)Medical Outcomes ReportedStudy Design
Pett RG et al. [26]PharmacistsPDMPFrequent PDMP users were more likely to recommend naloxone.Naloxone prescribed to shoppersExplanatory, sequential 2-phase mixed-methods
Durand et al. [27]Injured workers identified in worker’s compensation recordsPDMP and worker’s compensation claimsNo control group. Injured workers have a high prevalence of opioid use after injury, but prescribing patterns generally follow state guidelines.Not reportedRetrospective cohort
Freeman et al. [28]Pharmacists and providersInterviews about PDMPNo control group. Both PCPs and pharmacists reported PDMPs are key tools to aid prescribing and dispensing.Not reportedQualitative
Nagarajan and Talbert [29]Prescriber-prescriber networksComputer modelOutliers were clearly identified in the model, which can help identify those prescribers contributing to the opioid epidemic.Not reportedComputer model to detect prescriber outliers
Perry et al. [30]Patients who submitted claims to commercial database in the Appalachian region of the U.S., 58.7% femaleComputer model PageRankModel clearly differentiates aberrant behavior identifying drug shoppers for both opioids and morphine milligram equivalents (MME).Not reportedComputer model to detect prescriber outliers
Soffin et al. [31]n/aPDMPn/aAccessing real-time information about patients’ prescription opioid status using PDMP reduces opioid quantities prescribedOpinion
Stopka et al. [32]adults in Massachusetts prescribed opioidsComputer modelHotspots were identified.Not reportedSpatial epidemiological study
Wang et al. [33]Patients in pharmacological database in FloridaPharmacological databaseRecipients of opioids, benzodiazepines, and carisoprodol in 2017 compared with 2012 were younger, more likely to be female, and geographically-localized.Not reportedRetrospective, observational
Butler et al. [34]n/aPDMP, Lock-in programsNo control group. The lock-in program decreased doctor shopping.Broader range of drug schedules and an increases frequency of updating the PDMP results in lower opioid-related mortalityOpinion
Lin et al. [35]Patients from health insurance claim dataMedication record sharing programThe medication duplication rate was reduced 7.76 percentile, average medication overlap periods shortened 4.36 days.Not reportedRetrospective pre-post test design
Ponte et al. [36]Beneficiaries of the France public health systemSNIIRAM databaseThe strong opioid analgesics have the highest DSI (2.79%) versus 2.06% for BZD hypnotics. Flunitrazepam ranked first according to its DSI (13.2%), followed by morphine (4%), and zolpidem (2.2%). Not reportedRetrospective, observational
Torrance et al. [37]Beneficiaries of the Scotland National Health System (NHS)NHS and Generation Scotland databases combined to identify trendsThe number of strong opioid prescriptions more than doubled between 2003–2012. Patients in the most deprived areas were more likely to receive a strong opioid.Not reportedDescriptive analysis
Ali et al. [38]Respondents to the national survey of drug use and health, aged 12 and older, 48% maleSurvey instrument to assess effectiveness of the PDMPNo control group. PDMP was effective at controlling for doctor shopping for opiate pain killers.10–20 fewer days of NMPR useQualitative
Rutkow et al. [39]Prescribers in four statesPDMPPrescribers need to work with law enforcement, law-enforcement need to share data with each other, data sharing between states needs to occur.Not reportedQualitative
Simeone [40]PrescriptionsPDMP, education efforts, pharmacy panels that span the countryNo control group. The number of prescriptions diverted fell from 4.3 million in 2008 to 3.37 million in 2012.Decline in overdose mortalityRetrospective, observational
Chenaf et al. [17]Adult patients with chronic non-cancer pain (CNCP)French national health systemNo control group. Shopping very low in drugs for these conditions.Not reportedRetrospective cohort
Delorme et al. [42]Patients treated by opioid substitution treatment over 8 yearsFrench national health systemNo control group. Shopping behavior was only found in high dosage buprenorphine patients, but still very low.Not reportedRetrospective cohort
Kea et al. [43]Emergency Department (ED) dischargesPDMPDoctor shopping was not detected in ED survey.Not reportedQualitative
Table 2. Summary of analysis.
Table 2. Summary of analysis.
AuthorsIntervention ThemeOutcome ThemeFacilitator ThemeBarrier Theme
Pett et al.PDMPShoppers prescribed treatmentPharmacists supportNot reported
Durand et al.CombinationNot reportedGovernment supportData sharing
Freeman et al.PDMPNot reportedGovernment supportAccess not mandatory
Pharmacists support
Prescriber support
Nagarajan and Talbert Computer modelNot reportedSimple to implementNot reported
Perry et al.Computer modelNot reportedNot reportedNot reported
Soffin et al.PDMPReduced opioids prescribedGovernment supportNot reported
Prescriber support
Stopka et al.Computer modelNot reportedSimple to implementNot reported
Wang et al.OtherNot reportedGovernment supportNot reported
Butler et al.CombinationReduced mortalityMust use lawAccess not mandatory
Does not treat addiction
Lin et al.OtherNot reportedGovernment supportNot reported
Ponte et al.National health system database (DB)Not reportedGovernment supportNot reported
Torrance et al.National health system DBNot reportedGovernment supportNot reported
Ali et al.PDMPFewer days of useNot reportedNot reported
Rutkow et al.PDMPNot reportedGovernment supportData sharing
Simeone CombinationReduced mortalityGovernment supportEasily thwarted
Pharmacists support
Chenaf et al.National health system DBNot reportedGovernment supportNot reported
Delorme et al.National health system DBNot reportedGovernment supportNot reported
Kea et al.PDMPNot reportedGovernment supportNot reported
National Council of State Boards of NursingPDMPNot reportedGovernment supportNot reported
Okumura et al.National health system DBNot reportedGovernment supportNot reported
Ong et al.Health insurance claimsNot reportedGovernment supportData sharing
Prescriber support
Takahashi et al.Computer modelNot reportedSimple to implementNot reported
Huang et al.OtherNot reportedCost savingsParticipation not mandatory
Government supportAccess not mandatory
Lin et al.Health insurance claimsNot reportedGovernment supportNot reported
Lu et al.Health insurance claimsNot reportedGovernment supportNot reported
Webster and Grabois PDMPNot reportedGovernment supportAccess not mandatory
Han et al.PDMPReduced shoppingNot reportedNot reported
Hypponen et al.Health information exchangeNot reportedGovernment supportNot reported
Cost savings
Increased efficiency
Shepherd CombinationNot reportedNot reportedInadequate data collection
Ineffective data use
Data sharing
Constraints on enforcement
Cash-only not captured
Cepeda et al.PDMPReduced shoppingNot reportedData sharing
Modarai et al.OtherNot reportedGovernment supportNot reported
Rouby et al.National health system DBNot reportedGovernment supportNot reported
Simoni-Wastila and Qian PDMPNo decline in mortalityGovernment supportNot reported
Worley et al.PDMPReduced shoppingGovernment supportNot reported
Prescriber support
Worley et al.PDMPNot reportedGovernment supportNot reported
Prescriber support
Fass and Hardigan PDMPNot reportedGovernment supportNot reported
Frauger et al.OtherNot reportedGovernment supportNot reported
Hincapie et al.Health information exchangeNot reportedGovernment supportParticipation not mandatory
Hsu et al.CombinationNot reportedPrescriber supportParticipation not mandatory
Pauly et al.Computer modelNot reportedGovernment supportNot reported
Wilsey et al.PDMPNot reportedGovernment supportNot reported
Pradel et al.National health system DBNot reportedGovernment supportNot reported
Table 3. Summary of quality assessments.
Table 3. Summary of quality assessments.
Strength of EvidenceFrequencyQuality of EvidenceFrequency
III (Non-experimental, qualitative)28 (67%)A (High quality)25 (60%)
IV (Opinion)10 (24%)B (Good quality)11 (26%)
II (Quasi-experimental)4 (10%)C (Low quality or major flaws)6 (14%)
I (Experimental study or RCT)0 (0%)
(a)(b)
Table 4. Affinity matrix of Health Information Technology (HIT) interventions to control for doctor shopping.
Table 4. Affinity matrix of Health Information Technology (HIT) interventions to control for doctor shopping.
InterventionsReferencesOccurrences (n = 42)Frequency
PDMP[13,26,28,31,38,39,41,43,49,50,51,54,55,56,60]1536%
National health system DB[17,36,37,42,44,53,61]717%
Computer model[29,30,32,46,59]512%
Combination[11,16,27,34,54]512%
Other[15,33,35,52,57]512%
Health insurance claims[45,47,48]37%
Health information exchange[14,58]25%
Table 5. Affinity matrix of facilitators of Health Information Technology (HIT)to control for doctor shopping.
Table 5. Affinity matrix of facilitators of Health Information Technology (HIT)to control for doctor shopping.
FacilitatorsReferencesOccurrences (n = 52)Frequency
Government support[13,14,17,27,28,31,33,35,36,37,39,40,41,42,43,44,45,47,48,49,52,53,54,55,56,57,58,59,60,61]3160%
Prescriber support[28,31,45,55,56]612%
Not reported[11,30,38,50,51]510%
Simple to implement[29,30,32,46]46%
Pharmacists support[26,28,40]36%
Cost savings[14,15]24%
Must use law[34]12%
Increased efficiency[14]12%
Table 6. Affinity matrix of barriers of Health Information Technology (HIT)to control for drug shopping.
Table 6. Affinity matrix of barriers of Health Information Technology (HIT)to control for drug shopping.
BarriersReferencesOccurrences (n = 48)Frequency
Not reported[13,14,17,26,29,30,31,32,33,35,36,37,38,41,42,43,44,46,47,48,50,52,54,55,56,57,59,60,61]3063%
Data sharing[11,27,39,45,51]510%
Access not mandatory[15,28,34,49]48%
Participation not mandatory[15,16,58]36%
Easily thwarted[40]12%
Inadequate data collection[11]12%
Ineffective data use[11]12%
Constraints on enforcement[11]12%
Cash-only not captured[11]12%
Does not treat addiction[34]12%
Table 7. Affinity matrix of medical outcomes commensurate with Health Information Technology (HIT) as intervention.
Table 7. Affinity matrix of medical outcomes commensurate with Health Information Technology (HIT) as intervention.
Medical OutcomesReferencesOccurrences (n = 42)Frequency
Not reported[11,13,14,15,16,17,27,28,29,30,32,33,35,36,37,39,41,42,43,44,45,47,48,49,52,53,56,57,58,59,60,61]3379%
Reduced shopping[50,51,55]37%
Reduced mortality[34,40]25%
Shoppers prescribed treatment[26]12%
Fewer days of use[38]12%
No decline in mortality[54]12%
Reduced opioids prescribed[31]12%

Share and Cite

MDPI and ACS Style

Kruse, C.S.; Kindred, B.; Brar, S.; Gutierrez, G.; Cormier, K. Health Information Technology and Doctor Shopping: A Systematic Review. Healthcare 2020, 8, 306. https://doi.org/10.3390/healthcare8030306

AMA Style

Kruse CS, Kindred B, Brar S, Gutierrez G, Cormier K. Health Information Technology and Doctor Shopping: A Systematic Review. Healthcare. 2020; 8(3):306. https://doi.org/10.3390/healthcare8030306

Chicago/Turabian Style

Kruse, Clemens Scott, Brady Kindred, Shaneel Brar, Guillermo Gutierrez, and Kaleigh Cormier. 2020. "Health Information Technology and Doctor Shopping: A Systematic Review" Healthcare 8, no. 3: 306. https://doi.org/10.3390/healthcare8030306

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop